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Abstract
Objective—This study examined racial/ethnic differences in the prevalence of diabetes mellitus
in a nationally representative sample of adults with and without common psychiatric disorders.
Method—Data were drawn from Wave 2 of the National Epidemiologic Survey on Alcohol and
Related Conditions (N= 34,653). Logistic regression models adjusting for sociodemographic
variables and diabetes risk factors were used to examine racial/ethnic differences in 12-month
prevalence rates of diabetes by psychiatric status.
Results—Among people without psychiatric disorders, African Americans, Hispanics, and
American Indians/Alaska Natives, but not Asians/Pacific Islanders, had significantly higher rates
of diabetes than non-Hispanic whites even after adjusting for socio-demographic variables and
diabetes risk factors. In the presence of psychiatric disorders, these health disparities persisted for
African Americans and Hispanics, but not for American Indians/Alaska Natives. No significant
interactions between race/ethnicity and psychiatric disorders in the odds of diabetes were found
across any group.
Conclusion—Policies and services that support culturally appropriate prevention and treatment
strategies are needed to reduce racial/ethnic disparities in diabetes among people with and without
psychiatric disabilities.
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Diabetes mellitus is a common and disabling condition among racial/ethnic minorities in the
United States and people with psychiatric disorders. Presently, it afflicts 7.8% of the general
population and is the sixth leading cause of death nationwide [1]. U.S. racial and ethnic
minority groups, particularly African Americans, Hispanics, and American Indians/Alaskan
Natives, are disproportionately impacted by diabetes and suffer higher levels of morbidity
and mortality due to this chronic illness [2,3]. The age-adjusted prevalence of diabetes is
higher among American Indians (16.5%), African Americans (11.8%), and Hispanics
(10.4%) than among Asian Americans (7.5%) and non-Hispanics whites (6.6%) [4].
People with psychiatric disorders, such as major depression, bipolar disorder, and substance
use disorders, are at increased risk for diabetes and other chronic medical conditions
compared to the general population [5]. The comorbidity of diabetes and psychiatric
disorders is common and associated with reduced functioning and quality of life and
elevated mortality rates [6,7]. For instance, depressive disorders are present in
approximately 10% to 30% of patients with diabetes and increase the risk for diabetes-
related complications, such as blindness, myocardial infarctions, and stroke [8,9]. Diabetes
is also prevalent among people with anxiety disorders [10] and among those with heavy
alcohol use (more than three drinks a day) [11]. Compared to people without psychiatric
conditions, people with psychotic disorders (e.g., schizophrenia) are about twice as likely to
have diabetes [12]. Less is known about the prevalence of diabetes among people with
substance use disorders and personality disorders. Substance use disorders, including
alcohol abuse and dependence, seem to increase the risk for diabetic complications [13] and
to be more frequently associated with diabetes when comorbid with psychotic disorders [7].
Personality disorders might be less prevalent among people with diabetes than in the general
population [14] with the exception of antisocial [15] and borderline personality disorders
[16].
There are good reasons to expect that the combination of racial/ethnic minority status and
the presence of a psychiatric disorder may increase the risk of diabetes. Racial/ethnic
minorities face numerous risk factors, such as higher rates of obesity, insulin resistance, and
physical inactivity, as well as poor access to health care, that place them at elevated risk for
diabetes [17-21]. The presence of a psychiatric disorder may exacerbate these risks for
racial/ethnic minorities in several ways. First, the higher rates of obesity and insulin
resistance in racial and ethnic groups, particularly African Americans and Hispanics, may
place them at greater risk for negative metabolic alterations associated with psychotropic
medications (e.g., second-generation antipsychotics) that increase the risk of diabetes.
Evidence for this greater susceptibility to antipsychotic-induced glucoregulatory
complications among African Americans and Hispanics with schizophrenia was found in a
6-month, randomized, double blind study of risperidone and olanzapine [22]. Second, the
social and cognitive deficits associated with psychiatric disabilities may amplify the existing
difficulties racial and ethnic minorities face in communicating with their medical providers
[3], thus compromising their access and involvement in appropriate medical care. Third,
mistrust of the medical establishment due to past experiences of racism - a known obstacle
to medical care for racial/ethnic minorities [3] - may be compounded by the stigma
associated with the presence of a psychiatric condition.
Recent studies indicate that racial and ethnic minorities, particularly African Americans and
Hispanics, with common psychiatric disorders (e.g., major depression) report higher rates of
diabetes than non-Hispanic whites with similar psychiatric conditions [12,17,23,24]. For
instance, African American race, obesity, and a diagnosis of depression each independently
increased the risk of diabetes in a large primary care sample (n=8,179), and these risk factors
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significantly interacted to create a multiplicative burden of developing diabetes among
African Americans compared to non-Hispanic whites [25]. These studies, however, are
mostly based on clinical samples and focused on one mental disorder. Few studies have used
standardized psychiatric diagnostic instruments and examined racial/ethnic differences in a
sufficiently large community sample to study the interaction of race/ethnicity with other risk
factors while including racial/ethnic groups other than non-Hispanic whites, African
Americans, and Hispanics.
The current study builds upon this literature and addresses many of the methodological
limitations listed above by using a large multi-ethnic nationally representative community
sample and structured diagnostic interviews to examine racial/ethnic differences in diabetes
among people with a variety of psychiatric conditions including mood, anxiety, substance
use, and personality disorders. Given the combination of two known diabetes risk factors,
we hypothesized that: a) the rates of diabetes will be higher for African Americans,
Hispanics, American Indians/Alaska Natives (AI/AN), and Asians/Pacific Islanders (A/PI)
with and without psychiatric disorders than for non-Hispanic Whites with similar psychiatric
status even after adjusting for sociodemographic variables and other diabetes risk factors
(e.g., body mass index [BMI], other medical conditions, and lifetime use of psychotropic
medications); and b) race/ethnicity and the presence of psychiatric disorders will have an
interactive effect on risk, resulting in higher vulnerability of diabetes among racial/ethnic
minority groups compared to non-Hispanic whites.
2. Methods
2.1. Sample
The 2004-2005 Wave 2 sample of the National Epidemiologic Survey on Alcohol and
Related Conditions (NESARC) was used in the present study. A detailed description of the
NESARC Wave 1 and 2 methodology is reported elsewhere [26,27]. The NESARC is based
on a nationally representative sample of the U.S. non-institutionalized population 18 years
of age or older who reside in households and group quarters (e.g., college dormitories, group
homes, boarding homes) throughout the 50 states and the District of Columbia. African
Americans, Hispanics, and adults ages 18-24 were oversampled, with data adjusted for
oversampling, household- and person-level non-response. All procedures, including
informed consent, received full ethical review and approval from the U.S. Census Bureau
and U.S. Office of Management and Budget.
The Wave 1 NESARC surveyed 43,093 respondents, yielding a response rate of 81% [19].
Respondents from Wave 1 who were deceased (n=1,403), deported, mentally or physically
impaired (n=781) or on active military duty (n=950) were ineligible to be re-interviewed in
Wave 2 [28]. The total sample for the present study included the 34,653 respondents who
were re-interviewed in Wave 2, yielding a response rate of 86.7%. Sample weights are
described elsewhere [27] and were developed to adjust for Wave 2 non-response,
sociodemographic factors and the presence of any psychiatric diagnoses in Wave 1.
Weighted data were adjusted to be representative of the U.S. civilian population based on
estimates from the 2000 census.
2.2. Measures
2.2.1. Psychiatric Diagnostic Assessment—Diagnostic assessments of past-year
mood, anxiety, and substance use disorders, and lifetime personality disorders were derived
from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcohol Use
Disorder and Associated Disabilities Interview Schedule – DSM-IV version (AUDADIS-
IV), Wave 2 version [26]. The AUDADIS-IV is a structured diagnostic interview designed
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for use by lay interviewers in large-scale surveys [26,29]. Previous studies indicate that the
AUDADIS-IV measures for mood, anxiety and substance abuse disorders show adequate
reliability (e.g., test-retest) and validity (e.g., convergent, construct) among general
population samples and racial and ethnic minority groups [30,31-34]
In the present study, we used aggregate variables for any mood disorders, any anxiety
disorders, and any substance use disorders in the past 12 months, and any lifetime
personality disorders. Any mood disorders included major depressive disorder, dysthymia,
bipolar I and bipolar II. Any anxiety disorders included generalized anxiety disorder, panic
disorder (with or without agoraphobia), social anxiety disorder, specific phobia, and
posttraumatic stress disorder. Mood and anxiety disorders that were substance-induced or
caused by a general medical condition or bereavement were excluded. Any substance use
disorders included abuse and/or dependence for alcohol and/or 11 classes of drugs:
sedatives, tranquilizers, nicotine, opiates (other than heroin or methadone), stimulants,
hallucinogens, cannabis, cocaine (including crack cocaine), inhalants/solvents, heroin and
other drugs. Any lifetime personality disorders included antisocial, avoidant, dependent,
obsessive-compulsive, paranoid, schizoid, schizotypal, narcissistic, borderline, and
histrionic. A global indicator of any psychiatric disorder was developed that included the
presence of any of the disorders presented above.
2.2.2. Diabetes and other medical conditions—The AUDADIS-IV section assessing
medical conditions was used to develop indicators for diabetes mellitus and other medical
conditions, including cardiovascular disease (CVD; defined as hardening of the arteries or
arteriosclerosis; chest pain or angina pectoris; rapid heartbeat or tachycardia; heart attack or
myocardial infarction; stroke and/or any other form of heart disease), high cholesterol, high
blood pressure or hypertension, liver disease, gastritis or stomach ulcer, HIV/AIDS, sexually
transmitted disease or venereal disease, and arthritis. The presence of these health conditions
was determined by two questions. Participants were first asked whether they had a particular
medical condition (e.g., diabetes) in the last 12 months. If they answered “yes”, then they
were asked whether this diagnosis was confirmed by a doctor or other health professional.
Those responding “yes” to both questions were categorized as having the medical condition
in question (0 = absent, 1 = present). To account for the presence of other medical
conditions in our multivariate models that did not include diabetes, a continuous variable
representing the total number of medical conditions endorsed by each participant was
created for the present study.
Self-reported height and weight were used to compute participants’ body mass index (BMI)
by dividing weight in kilograms by the square of height in meters. To describe the sample’s
BMI, participants were classified into one of four groups: underweight (BMI < 18.5),
normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9), and obese (BMI ≥ 30). Given
that the use of some psychotropic medications is linked to diabetes, we included a global
indicator of lifetime use of psychotropic medications in our multivariable models.
Participants were asked if a doctor had ever prescribed medications for symptoms of each
mood and anxiety disorder assessed, but specific medications were not coded. A
dichotomous variable (No = 0, Yes = 1) was created to capture participants’ lifetime use of
these medications.
2.2.3. Sociodemographics—Sociodemographic variables included gender, age, marital
status, education, and annual family income. Race and ethnicity were determined by self-
identification. Five groups were included: non-Hispanic whites (n = 20,161), African
Americans (n = 6,587), Hispanics (n = 6,359), AI/AN (n = 578), and A/PI (n = 968).
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Weighted percentages and means were computed to describe the sociodemographic,
physical and mental health characteristics of the sample stratified by race/ethnicity. Chi-
squares and Wald F-tests were used to determine the significance of differences between
percentages and means, respectively. Odds ratios (ORs), derived from a series of logistic
regression analyses, evaluated racial/ethnic differences in past-year diabetes rates among
people with psychiatric diagnoses. Non-Hispanics whites were the reference group for these
analyses. To examine whether the diabetes prevalence rates across racial/ethnic groups was
moderated by the presence of psychiatric disorders, we used logistic regression models with
diabetes as the outcome and race, presence of psychiatric disorder, and their interaction as
predictors. A model was run for each psychiatric disorder. All models adjusted for
sociodemographic variables (gender, age, marital status, education and family income) and
diabetes risk factors (BMI, other medical conditions, and lifetime use of psychotropic
medications), and all predictors (including interactions) were considered significant at
α=0.05 level, two-tailed. Approximately, less than 3% of the sample reported missing data
in the independent and dependent variables included in our models. All models were re-
examined excluding cases with missing data and no changes in the direction and
significance of the findings were found, thus results presented in this paper include models
with missing data. Standard errors and 95% confidence intervals for all analyses were
estimated using SUDAAN [35], a software package that uses Taylor series linearization to
adjust for the design effects of complex sample surveys like the NESARC.
3. Results
3.1. Sample Characteristics
The sample was composed of 58% non-Hispanic whites, 19% African Americans, 18%
Hispanics, 2% AI/AN and 3% A/PI (See Table 1). Considerable differences were found
across racial/ethnic groups. African Americans had the largest percentage of females,
whereas Hispanics had the highest percentage of males. Non-Hispanic whites on average
were the oldest group and Hispanics were the youngest. A/PI had the largest proportion of
participants who were married or living with someone, whereas African Americans had the
highest proportion of widowed, separated, or divorced participants. Hispanics had the
highest proportion of participants with less than a high school education, whereas non-
Hispanic whites and A/PI had the highest proportion of participants with some college or
higher. African Americans, Hispanics, and AI/AN reported the highest percentages of
families making less than $20,000 per year.
In regards to the physical health and mental health characteristics of the sample, African
Americans and Hispanics had the highest proportion of participants who were overweight or
obese (BMI ≥25). The 12-month prevalence of diabetes was highest among AI/AN (12.3%)
followed by African Americans (11.5%), and Hispanics (8.5%). The lowest rates of diabetes
were found for non-Hispanic whites (7.6%) and A/PI (5.9%). AI/AN reported the highest
rates of 12-month cardiovascular disease, liver, gastritis/stomach ulcers, sexually transmitted
disease, and arthritis. High cholesterol was more prevalent among non-Hispanic whites and
AI/AN. African Americans reported the highest rates of hypertension and HIV/AIDS. AI/
AN reported the highest prevalence of all psychiatric disorders. Lifetime use of psychotropic
medication was highest among AI/AN and lowest among A/PI.
3.2. Racial and Ethnic Differences in Diabetes by Psychiatric Status
Table 2 shows the unadjusted prevalence rates of diabetes by psychiatric disorders stratified
by racial/ethnic groups. Significant racial/ethnic differences in diabetes rates were found by
psychiatric status. In the absence of psychiatric diagnoses, AI/AN reported the highest
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prevalence rates of diabetes followed by African Americans and Hispanics. A/PI and non-
Hispanic whites had the lowest rates of diabetes among people without psychiatric
diagnoses. The presence of psychiatric disorder had a differential impact on diabetes rates
across racial/ethnic groups. For non-Hispanic Whites, AI/AN, and A/PI, diabetes rates
decreased in the presence of any-psychiatric, substance abuse, and mood disorders in the
past year. However, diabetes rates increased for all three racial/ethnic groups with past-year
anxiety disorders and marginally increased for non-Hispanic Whites and AI/AN with
lifetime personality disorders. For African Americans and Hispanics, diabetes rates
increased in the presence of any-psychiatric, mood, and anxiety disorders in the past year
and in lifetime personality disorders. Yet, diabetes rates decreased for both groups in the
presence of past-year substance abuse disorders. For any-psychiatric, substance use, mood,
and anxiety disorders in the past year, African Americans reported the highest rates of
diabetes followed by Hispanics and AI/AN. For lifetime personality disorders, AI/AN
reported the highest levels of diabetes followed by African Americans and Hispanics.
Table 3 shows results from logistic regression models comparing the prevalence of diabetes
between non-Hispanic whites and each of the racial/ethnic groups stratified by psychiatric
disorders and adjusting for sociodemographic variables and diabetes risk factors. African
Americans and Hispanics reported significantly higher rates of diabetes than non-Hispanic
whites with and without psychiatric disorders. Moreover, the odds of having diabetes for
African Americans and Hispanics were higher in the presence of psychiatric disorders than
in the absence of any psychiatric disabilities. Among people without psychiatric disorders,
AI/AN reported significantly higher rates of diabetes than non-Hispanics whites. In contrast,
there were no significant differences in diabetes rates between AI/AN and non-Hispanic
whites with any of the psychiatric disorders examined. Similarly, no significant differences
in diabetes rates between A/PI and non-Hispanic whites were found. Tests of the
interactions between each racial/ethnic group and every psychiatric disorder in the odds of
diabetes found no significant differences (data available upon request).
4. Discussion
Our study is one of the few to date to examine racial/ethnic differences in diabetes rates
across common psychiatric disorders using a large multi-ethnic nationally representative
sample in the United States. Since racial/ethnic minority status and psychiatric disabilities
are two known diabetes risk factors, we hypothesized that the prevalence of diabetes will be
higher for racial/ethnic minorities with and without psychiatric disorders compared to non-
Hispanic Whites and that race/ethnicity and psychiatric disorders will interact resulting in a
higher vulnerability of diabetes among racial/ethnic minority groups. We found partial
support for our hypotheses.
Among people without psychiatric disorders, African Americans, Hispanics, and American
Indians/Alaska Natives (AI/AN), but not Asians/Pacific Islanders (A/PI), had significantly
higher prevalence rates of diabetes than non-Hispanic whites even after adjusting for
demographic and diabetes risk factors. In the presence of psychiatric disorders, these health
disparities clearly persisted for African Americans and Hispanics, but were found to be
statistically non-significant for AI/AN. These findings replicate previous results from
clinical studies reporting disparities in diabetes prevalence for African Americans and
Hispanics with schizophrenia [12,23] and major depression [25], and extend these racial/
ethnic disparities to African Americans and Hispanics with past-year anxiety and substance
use disorders, and lifetime personality disorders. Contrary to our hypothesis, our findings
also revealed no significant interactions between race/ethnicity and psychiatric disorders in
the odds of diabetes prevalence, suggesting that each of these is an independent diabetes risk
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factor. Taken together, these findings indicate that risk of diabetes among people with and
without psychiatric disorders is not uniform and varies across racial/ethnic groups.
No significant differences in diabetes rates were observed between non-Hispanics whites
and A/PI regardless of psychiatric status, sociodemographic variables, and other diabetes
risk factors. Considerable genetic, ethnic, socioeconomic, linguistic, and cultural diversity
exists in the A/PI U.S. population. This variability may have masked important differences
in diabetes rates within these heterogeneous groups. For example, diabetes and heart disease
rates are higher among Asian Indians and Filipinos and lower among Koreans, Vietnamese,
and Chinese in the U.S. (36,37). Moreover, Pacific Islanders (e.g., Native Hawaiians,
Samoans) have higher rates of diabetes than other Asian American groups and non-Hispanic
whites (38). More research is warranted to better clarify how various risk factors vary
among the growing A/PI population and impact their health risk and health status, including
diverse lifestyles related to culture, diet, family structure, perceptions of body image,
physical activity, and acculturation to Western diets and culture (36).
Consistent with previous studies, AI/AN without psychiatric disorders had significantly
higher rates of diabetes compared to non-Hispanics whites even after adjusting for
sociodemographic variables and other diabetes risk factor [3]. These differences, however,
were no longer significant in the presence of common psychiatric disorders. A closer
examination of our logistic models showed that BMI and the total number of other medical
conditions accounted for the differences in diabetes rates between non-Hispanics whites and
AI/AN (data available upon request). These findings should be interpreted with caution as
the small sample size of AI/AN in our study may have contributed to the loss of power to
detect significant differences when compared to non-Hispanics whites once all covariates
were included in our models. Future studies are needed to confirm these findings with a
larger community sample of AI/AN. Nonetheless, our results suggest that policies that target
obesity and improve the treatment of comorbid medical conditions among AI/AN may help
reduce risk of diabetes in this vulnerable population.
Compared to non-Hispanic whites with and without psychiatric disorders, African
Americans and Hispanics were disproportionately impacted by diabetes even after adjusting
for socio-demographic variables and common diabetes risk factors. The presence of a
psychiatric disorder significantly increased the odds of diabetes prevalence for African
Americans and Hispanics, but did not seem to create an additive effect beyond the burden
already present by their racial/ethnic minority status. These findings suggest that for African
Americans and Hispanics common psychiatric conditions and racial/ethnic minority status
are each independent risk factors for diabetes. African Americans and Hispanics in the U.S.
face an accumulation of genetic, environmental, and lifestyle factors that magnify their
vulnerability to develop diabetes [17-20], and these in turn are exacerbated by poor access to
high-quality medical care [3]. Our findings indicate that psychiatric conditions significantly
contribute to this vulnerability. Given that this is a largely understudied area, more research
is needed to clarify the impact of psychiatric conditions and mental health care on the onset
and course of diabetes among African Americans and Hispanics. A fertile area for future
research is to examine how exposure to psychotropic medications with known
cardiometabolic side effects increases diabetes vulnerability among African Americans and
Hispanics, given their predispositions to this costly and disabling condition. Moreover,
studying the links between onset and course of diabetes, biological predispositions, and
social determinants (such as stigma, racism, and differential access to medical and mental
health care) can also help clarify the mechanisms that create these health inequalities among
African Americans and Hispanics.
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The higher prevalence of diabetes among African Americans, Hispanics, and AI/AN with
and without psychiatric disorders indicates that systematic efforts to screen and monitor the
physical health of these groups in both mental health and primary care settings are needed.
Expert consensus guidelines for the physical health monitoring of people with mental
disorders [39,40] provide the basis for these efforts and if implemented across settings of
care could set the stage for improved detection and management of diabetes in these at-risk
populations. Models of integrated physical and mental health care (e.g., co-located and
collaborative care [41-43], lifestyle interventions [44,45], and care management programs
[46]) are another viable strategy recommended by the Institute of Medicine to improve the
prevention and treatment of diabetes and other chronic medical illnesses among people with
psychiatric conditions [5]. Given the multiple determinants of diabetes and psychiatric
comorbidities, a one-size-fits-all approach is not appropriate for this complex health
problem. Prevention and treatment strategies must be multi-level and take into consideration
patients’ needs, preferences, lifestyle choices, socioeconomic status, and cultural resources
and strengths; providers’ skills, training and supports; organizational structures and policies
for supporting culturally appropriate diabetes prevention and care; and community resources
and infrastructures for enhancing and sustaining health promotion and general wellness.
Several study limitations warrant consideration. Ascertainment of diabetes, BMI, other
health conditions, and the lifetime use of psychotropic medications was based on self-report
measures and did not distinguish between Type 1 and Type 2 diabetes. Self-report measures
tend to underestimate rates of physical health conditions. For example, compared to medical
or laboratory records, self-reported diabetes measures tend to underestimate the prevalence
of diabetes [47], thus the prevalence of diabetes in this study are most likely under-reported.
The cross-sectional nature of our analyses prevented us from determining causation. Our
analyses did not include people with a diagnosis of schizophrenia as it was not assessed in
the AUDADIS-IV. Moreover, psychosis was also excluded from our analyses because it was
assessed with one self-report question of unknown diagnostic reliability and validity and few
people endorsed this item, restricting the power for meaningful statistical comparisons. Our
analyses may mask important within-group differences in the comorbidity of diabetes and
psychiatric conditions. Great diversity in risk factors and prevalence rates exists within
racial/ethnic groups. For example, in the diverse Hispanic population, prevalence rates of
diabetes and psychiatric conditions vary by country of origin, language preference, and
acculturation levels [48,49]. Future studies that unpack within-group differences in racial/
ethnic minority populations are needed to better identify and understand health disparities
and develop targeted services and policies to help eliminate inequalities in disease burden
and quality of care.
This study presents racial and ethnic differences in diabetes prevalence in a nationally
representative community sample of people with a variety of psychiatric disabilities. These
racial and ethnic inequalities mirror the diabetes disparities observed in the general U.S.
population and indicate that racial/ethnic minority status, particularly for African Americans
and Hispanics, and psychiatric disorders are both independent risk factors for this costly and
disabling condition. Culturally and linguistically appropriate prevention and treatment
strategies are needed to reduce the negative impact of diabetes and its complications among
racial/ethnic minority communities and help eliminate the unnecessary suffering caused by
these health disparities.
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